Dr. Robert Wenham, principal investigator of Anixa's Phase 1 clinical trial at Moffitt Cancer Center, to present on December 14 in LondonSAN JOSE, Calif., Nov. 4, 2026 /PRNewswire/ -- Anixa Biosciences,
First patient in fifth cohort exhibiting stable disease 90 days after treatmentMultiple patients surviving more than one year, including one beyond two years, with no dose-limiting toxicities observed to datePatients in
Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conferenceSAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")
First patient in current dose cohort exhibited no progression of her cancer three months aftertreatmentMultiple patients have survived more than one year, including one beyond two yearsNo dose-limiting toxicities
Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to DatePatients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following LymphodepletionSAN
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estateContinues expansion of global intellectual
SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today
SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today
Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt Cancer CenterSAN JOSE, Calif., Sept. 3, 2026 /PRNewswire/ -- Anixa
Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoingOvarian cancer CAR-T therapy, lira-cel, advances to
Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 monthsBreast cancer vaccine
Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platformContinues expansion of global intellectual property coverage in markets with increasing breast cancer incidence
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to DatePatients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estateExpands global intellectual property
Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participantsOvarian cancer CAR-T therapy, lira-cel,
